Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3015-3023

  Boone, Julien J M ^a   Bhosle, Jaishree ^a   Tilby, Mike J ^b   Hartley, John A ^a   Hochhauser, Daniel ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; COMET ASSAY; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; FEMALE; HUMANS; RECEPTOR, ERBB-2; TRANSFECTION;

EID: 70949095656     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0219     Document Type: Article

References (50)

1. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-182
2. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987;84:7159-7163
3. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137
5. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365
6. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225
7. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007;26:6577-6592
8. Giri DK, Ali-Seyed M, Li LY, et al. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005;25:11005-11018 (Pubitemid 41747142)
9. Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 2007;282:10432-10440
10. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005;65:338-348 (Pubitemid 40070827)
11. Wang SC, Lien HC, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004;6:251-261 (Pubitemid 39222038)
12. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
13. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749
14. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251
15. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-769
16. Naruse I, Fukumoto H, Saijo N, Nishio K. Enhanced anti-tumor effect of trastuzumab in combination with cisplatin. Jpn J Cancer Res 2002;93:574-581
17. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-2792
18. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-547
19. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004;9:518-527
20. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-2895
21. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
22. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063 (Pubitemid 30305105)
23. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro following treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839). Clin Cancer Res 2004;10:6476-6486 (Pubitemid 39346543)
24. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345 (Pubitemid 38944402)
25. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838
26. Martín M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986-991 (Pubitemid 24145327)
27. Jones AL, Smith IE, O'Brien ME, et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 1994;12:1259-1265
28. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112 (Pubitemid 20213250)
29. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced interstrand crosslinking using single-cell gel electrophoresis (Comet) assay. In: Brown R, Boger-Brown U, editors. Methods in molecular medicine, cytotoxic drug resistance mechanisms. Totowa (NJ): Humana Press; 1999, p. 143-154
30. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-512 (Pubitemid 29131958)
31. Olive PL. The comet assay. An overview of techniques. Methods Mol Biol 2002;203:179-194
32. Tilby MJ, Styles JM, Dean CJ. Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. Cancer Res 1987;47:1542-1546 (Pubitemid 17044480)
33. Tilby MJ, Johnson C, Knox RJ, Cordell J, Roberts JJ, Dean CJ. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using amonoclonal antibody. Cancer Res 1991;51:123-129
34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
35. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 (Pubitemid 32222155)
36. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249
37. Friedmann BJ, Caplin M, Savic B, et al. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 2006;5:209-218
38. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-3335 (Pubitemid 40524617)
39. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA, Hartley JA. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007;97:927-933 (Pubitemid 47519316)
40. Webley SD, Francis RJ, Pedley RB, et al. Measurement of the critical DNAlesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 2001;84:1671-1676
41. Corrie PG, Shaw J, Spanswick VJ, et al. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer 2005;92:1997-2003. (Pubitemid 40897421)
42. Hochhauser D, Meyer T, Spanswick VJ, et al. Phase 1 study of a sequence selective minor groove DNA binding agent (SJG 136) with pharmacokinetic and pharmacodynamic measurements in patients with advanced solid tumours. Clin Cancer Res 2009;15:2140-2147
43. Spanswick VJ, Craddock C, Sekhar M, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002;100:224-229 (Pubitemid 35177451)
44. Spanswick VJ, Lowe H, Newton C, et al. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand crosslinks in vitro and in clinical acquired resistant tumour samples (Abstract). Proc Am Assoc Cancer Res Apr 18-22: Denver, Colorado (CO): 2009. Abstract number 4619 2009:2146.
45. Hartley JA, Spanswick VJ, Brooks N, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-6699
46. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006;24:3735-3746
47. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005;11:7508-7515
48. Anido J, Scaltriti M, Bech Serra JJ, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006;25:3234-3244
49. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446 (Pubitemid 30208162)
50. Grazette LP, Boecker W, Matsui T, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004;44:2231-2238 (Pubitemid 39576044)